A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 1, 2008, Pages 204-211

  Bradbury, Penelope A ^a   Heist, Rebecca Suk ^b,c,d   Kulke, Matthew H ^b,e   Zhou, Wei ^c   Marshall, Ariela L ^b,c   Miller, David P ^c   Su, Li ^c   Park, Sohee ^c   Temel, Jennifer ^b,c,d   Fidias, Panos ^b,c,d   Sequist, Lecia ^b,d   Lynch, Thomas J ^b,d   Wain, John C ^b,d   Shepherd, Frances A ^a   Christiani, David C ^b,c,d   Liu, Geoffrey ^a,b,c,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ALGORITHM; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; ERROR; FEMALE; FISHER EXACT TEST; HUMAN; INFORMATION PROCESSING; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHARMACOGENETICS; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY CONTROL; STATISTICAL SIGNIFICANCE; TOXICITY; TREATMENT RESPONSE;

ALGORITHMS; CASE-CONTROL STUDIES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOGENETICS; PILOT PROJECTS; PROGNOSIS; QUESTIONNAIRES; SURVIVAL RATE;

EID: 38849144464     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0470     Document Type: Article

References (21)

1. Ambrosone CB, Rebbeck TR, Morgan GJ, et al. New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival. Cancer Epidemiol Biomarkers Prev 2006;15:2042-6.
2. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
3. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinibin lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
4. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumabplus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
6. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
7. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
8. Hung RJ, Boffetta P, Canzian F, et al. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res 2006;66:8280-6.
9. Long JR, Kataoka N, Shu XO, et al. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 2006;15:2115-22.
10. Moreno V, Gemignani F, Landi S, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006;12:2101-8.
11. Kader AK, Shao L, Dinney CP, et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 2006;66:11644-8.
12. Spitz MR, Wu X, Mills G. Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 2005;23:267-75.
13. Liu G, Zhou W, Wang Z, McLeod HL. Incorporating molecular oncology in prognosis. 3rd ed. In: Gospodarowicz MK, O'Sullivan B, Sobin L, editors. Prognostic factors in cancer. Hoboken (NJ): Wiley and Sons; 2006. p. 79-94.
14. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia (PA): Lippincott Williams and Wilkins; 1998.
15. Liu G, Miller DP, Zhou W, et al. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of nonsmall cell lung carcinoma. Cancer Res 2001;61:8718-22.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
17. Dikshit RP, Boffetta P, Bouchardy C, et al. Lifestyle habits as prognostic factors in survival of laryngeal and hypopharyngeal cancer: a multicentric European study. Int J Cancer 2005;117:992-5.
18. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434-40.
19. Kjaerbye-Thygesen A, Frederiksen K, Hogdall EV, et al. Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006;15:798-803.
20. Liu GG, Zhou S, Wang W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small cell lung cancer patients treated with gefitinib. Pharmacogenomics J. Epub 2007 Mar 20.
21. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005;11:1534-8.